Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.

The International journal of biological markers - 25 Jun 2014

Li Rui-Chao, Zheng Li-Jun, Fang Ming-Hao, Yu Shi-Ying

Abstract excerpt

Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. The presence of EGFR mutations was previously shown to confer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 24425324
DOI: 10.5301/jbm.5000059

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.PMID 24425324Read ↗

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Semantic proximity Read ↗

EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.Semantic proximity Read ↗

[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].Semantic proximity Read ↗

[Association between the epidermal growth receptor status and the efficacy of first-line chemotherapy in patients with advanced non-small cell lung cancer].Semantic proximity Read ↗

The clinical significance and function of EGFR mutation in TKI treatments of NSCLC patients.Semantic proximity Read ↗

Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.Semantic proximity Read ↗

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.Semantic proximity Read ↗

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?Semantic proximity Read ↗

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.Semantic proximity Read ↗

L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.